TFRC and non-Hodgkin lymphoma: As an example of this, the A24 monoclonal antibody that competitively binds to TFR1, inhibits Tf binding to TFR1, thus leading to TFR1 endocytosis and its downregulation at the cellular surface, and has shown proven efficacy against T-NHL (65, 66).